The Food & Drug Administration (FDA) has approved the Roche COBAS® TaqMan® HBV Test, the first assay for quantitating Hepatitis B Virus DNA approved in the US. The test uses Roche’s real-time PCR technology to quantify the amount of Hepatitis B virus DNA in a patient’s blood. Doctors may use viral load testing results to establish a baseline level of infection and during treatment as an aid in assessing individual responses to therapy.
Widespread application of antiviral therapy along with the Hepatitis B vaccine has helped reduce prevalence; however, Hepatitis B remains a serious and potentially life threatening global disease, potentially resulting in death from extensive liver damage or liver cancer for chronically infected people.1
"Viral load testing with an FDA approved test has long been the standard for managing patients with HIV and Hepatitis C," said Teresa Wright, MD, Chief Medical Officer at Roche Molecular Diagnostics. "Availability of this new Roche test enables doctors and laboratories to bring that same level of standardized viral load measurement to Hepatitis B treatment."
Because the goal of Hepatitis B therapy is to treat until the virus is undetectable in the patient’s blood, it is critical for viral load monitoring tests to be able to quantify very low levels of virus.
Similarly, it is important for the test to quantify very high levels of virus (higher than 100 million IU/mL), an indicator of the need for more or less aggressive treatment. The TaqMan HBV Test can detect the World Health Organization (WHO) HBV International Standard in plasma and serum as low as 3.5 IU/mL and 3.4 IU/mL respectively. The test can measure HBV DNA as high as 1.10E8 IU/mL, representing a significantly broader dynamic range than previously available tests in the U.S.
Other infections concomitant with Hepatitis B are common, with up to 10% of HIV patients in the US also infected with Hepatitis B virus. This makes it essential for the test to quantitate the HBV virus in presence of other viruses.
Designed for use with the High Pure System, the test is run on the TaqMan 48 analyzer and gives labs the added benefits of automated real-time PCR. The test system benefits from the same contamination control protection designed into all TaqMan assays, including closed-tube processing and built-in Roche-proprietary AmpErase enzymes. To help with needed standardization, the TaqMan HBV Test has been calibrated with the WHO standard and reports with the international unit of measure IU/mL. The test was designed to quantify all major Hepatitis B genotypes, including pre-core mutants that can lead to more severe liver disease and reduced response to antiviral therapy.
Source: PR Newswire